Elaskalani Omar, Razak Norbaini Binti Abdol, Falasca Marco, Metharom Pat
Omar Elaskalani, Norbaini Binti Abdol Razak, Pat Metharom, Platelet Research Laboratory, Curtin Health Innovation and Research Institute, Department of Health Sciences, Curtin University, Perth, Western Australia 6102, Australia.
World J Gastrointest Oncol. 2017 Jan 15;9(1):37-41. doi: 10.4251/wjgo.v9.i1.37.
Pancreatic cancer has one of the worst prognoses among all cancers due to the late manifestation of identifiable symptoms and high resistance to chemo- and radiation therapies. In recent years, a cancer development phase termed epithelial-mesenchymal transition (EMT) has gained increasing research focus. The process is implicated in tumour metastasis, and emerging evidence suggests EMT also contributes or induces chemoresistance in several cancers. Nevertheless, the applicability of therapeutic targeting of EMT faces many challenges. In this mini-review, we summarise the evidence supporting the role of EMT in pancreatic cancer progression, focusing particularly on its association with chemoresistance.
由于可识别症状出现较晚且对化疗和放疗具有高度抗性，胰腺癌是所有癌症中预后最差的癌症之一。近年来，一个被称为上皮-间质转化（EMT）的癌症发展阶段越来越受到研究关注。这个过程与肿瘤转移有关，并且新出现的证据表明EMT在几种癌症中也促成或诱导了化疗耐药性。然而，针对EMT进行治疗靶向的适用性面临许多挑战。在这篇小型综述中，我们总结了支持EMT在胰腺癌进展中作用的证据，尤其关注其与化疗耐药性的关联。
